Department of Surgery, CUHK

Dr WONG Alissa Michelle Go    

Research Assistant Professor

alissawongadd this for spam@add this for


Dr. Wong is a Research Assistant Professor in the Department of Surgery at The Chinese University of Hong Kong (CUHK). She holds a PhD from the Department of Clinical Oncology at The University of Hong Kong (HKU) and completed her post-doctoral training at the Department of Anatomical & Cellular Pathology, CUHK. Additionally, she served as a Visiting Research Scholar at the School of Pharmacy, University of Pittsburgh. Dr. Wong specializes in the development and application of patient-derived organoids for both basic and translational research purposes at the Laboratory for Cancer Organoid Research & Services, which operates under the Department of Surgery, CUHK.

Research Interests

  • Utilizing a multiomics approach to investigate the underlying mechanisms contributing to the development and recurrence of Hepatocellular carcinoma (HCC).
  • Exploiting pharmacogenomic vulnerabilities in HCC through the use of patient-derived organoid (PDO) culture systems.
  • Developing practical applications for solid tumor PDOs, bridging the gap between laboratory research and clinical practice.

Additional Information

Awards & Honors:

  • YS and Christabel Lung Postgraduate Scholarship 2012
  • Hong Kong Association for University Women Dr Thomas Cheung Postgraduate Scholarship 2011
  • Sir Edward Youde Postgraduate Scholarship 2010

Selected Publications

  1. Wong AM, Ding X, Wong AM, Xu M, Zhang L, Leung HHW, et al. Unique molecular characteristics of NAFLD-associated liver cancer accentuate β-catenin/TNFRSF19-mediated immune evasion. Journal of Hepatology. 2022;77(2):410–23.
  2. Lam YK, Yu J, Huang H, Ding X, Wong AM, Leung HH, et al. TP53 R249S mutation in hepatic organoids captures the predisposing cancer risk. Hepatology. 2022.
  3. Xu M, Liu Y, Wan HL, Wong AM, Ding X, You W, et al. Overexpression of nucleotide metabolic enzyme DUT in hepatocellular carcinoma potentiates a therapeutic opportunity through targeting its dUTPase activity. Cancer Letters. 2022;548:215898.
  4. Li Y, Chan JWY, Lau RWH, Cheung WY, Wong AM, Wong AM, Wong N, Ng CSH. Organoids in Lung Cancer Management. Front Surg. 2021 8:753801.
  5. Loong HF*, Wong AM*, Chan DTM*, Cheung MSH, Chow C, Ding X, Chan AKY, Johnston PA, Lau JYW, Poon WS, Wong N. Patient-derived tumor organoid predicts drugs response in glioblastoma: A step forward in personalized cancer therapy? J Clin Neurosci. 2020;78:400-402. *Co-first author
  6. Chan SL, Wong AM, Lee K, Wong N, Chan AK. Personalized therapy for hepatocellular carcinoma: Where are we now?. Cancer Treat Rev. 2016;45:77-86.
  7. Lau CC, Sun T, Ching AK, He M, Li JW, Wong AM, Co NN, Chan AW, Li PS, Lung RW, Tong JH, Lai PB, Chan HL, To KF, Chan TF, Wong N. Viral-human chimeric transcript predisposes risk to liver cancer development and progression. Cancer Cell. 2014;25(3):335-49.
  8. Wong AM, Kong KL, Chen L, Liu M, Zhu C, Tsang JWH, Guan XY. Characterization of CACNA2D3 as a putative tumor suppressor gene in the development and progression of nasopharyngeal carcinoma. Int J Cancer. 2013;133(10):2284-95.
  9. Zhang LY, Ho-fun lee V, Wong AM, Kwong DL, Zhu YH, Dong SS, Kong KL, Chen J, Tsao SW, Guan XY, Fu L. MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN. Carcinogenesis. 2013;34(2):454-63.
  10. Wong AM, Kong KL, Tsang JW, Kwong DL, Guan XY. Profiling of Epstein-Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs. Cancer. 2012;118(3):698-710.

Copyright © 2024. All Rights Reserved. Department of Surgery, The Chinese University of Hong KongCUHK

C O N T A C T   U S